THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Amgen (NASDAQ:AMGN), today announced upcoming data presentations of interest at the 43rd Annual American Society of Clinical Oncology (ASCO) Meeting in Chicago.
Clinical data will be presented on seven investigational therapies: AMG 531 in thrombocytopenic patients with myelodysplastic syndrome (MDS), motesanib diphosphate (AMG 706) in locally advanced or metastatic thyroid cancer; and AMG 102, AMG 386, AMG 479, AMG 655, and rhApo2L/TRAIL in patients with advanced solid tumors. This is the first time that Phase 1 clinical data for AMG 102, AMG 386, AMG 479 and AMG 655 will be presented. In addition, updated data from the Vectibix™ (panitumumab) 250 (EGFR low/negative) study, and health-related quality of life (QOL) and patient reported outcome (PRO) data from the pivotal 408 trial, will be presented.
